Mallinckrodt (MNK) Tops Q3 EPS by 16c, Miss on Revenues

Mallinckrodt plc (MNK) PT Lowered to $30 at Jefferies

Jefferies lowered its price target on Mallinckrodt plc (NYSE: MNK) to $30.00 (from $60.00) while maintaining a Buy rating.

Analyst Anthony Petrone said they picked up some data-points that suggest the Acthar fall-out is related to script denials in renal indications amongst... More

Mallinckrodt plc (MNK) PT Lowered to $27 at Morgan Stanley Citing Reduced Acthar Forecasts

Morgan Stanley lowered its price target on Mallinckrodt plc (NYSE: MNK) to $27.00 (from $40.00) while maintaining a Equalweight rating.

Mallinckrodt plc (MNK) PT Lowered to $50 at Stifel, Keeps Buy Rating

Stifel lowered its price target on Mallinckrodt plc (NYSE: MNK) to $50.00 (from $70.00) while maintaining a Buy rating.

Analyst Annabel Samimy takes a more conservative stance on Acthar citing unfilled prescriptions that highlight a greater industry-wide trend that raises concerns for the drug's LT... More

Wells Fargo Downgrades Mallinckrodt plc (MNK) to Market Perform

Wells Fargo downgraded Mallinckrodt plc (NYSE: MNK) from Outperform to Market Perform with a price target of $22.00 (from $60.00).

Analyst David Maris acknowledges that on metrics the equity appears "exceptionally undervalued" but remains cautious noting "in our experience, when new sales 'speedbumps; show... More

Mallinckrodt plc (MNK) PT Lowered to $40 at Piper Jaffray

Piper Jaffray lowered its price target on Mallinckrodt plc (NYSE: MNK) to $40.00 (from $67.00) while maintaining a Overweight rating.

Analyst David Amsellem acknowledges the quarter was "frustrating" but fails to see a reason to walk away from the equity noting cash flow generation should... More

Mallinckrodt plc (MNK) PT Lowered to $24 at Canaccord Genuity

Canaccord Genuity lowered its price target on Mallinckrodt plc (NYSE: MNK) to $24.00 (from $38.00) while maintaining a Hold rating.

Analyst Dewey Steadman believes Tuesday's selloff is now overdone noting many of the LT investors he spoke with "generally feel the same way" but... More

Barclays Downgrades Mallinckrodt plc (MNK) to Equalweight

Barclays downgraded Mallinckrodt plc (NYSE: MNK) from Overweight to Equalweight with a price target of $23.00 (from $65.00).

Analyst Douglas Tsao steps to the sidelines noting the slowdown in Acthar. The analyst notes that he lacks a reason to say the quarter disappointment is forecasting... More

Mallinckrodt plc (MNK) PT Lowered to $42 at Cantor Fitzgerald; Remains 'Overweight'

Cantor Fitzgerald analyst Louise Chen lowered her price target on Mallinckrodt plc (NYSE: MNK) to $42.00 (from $52.00) while maintaining an Overweight rating following Q3 results.

Chen notes the cut comes amid lower sales for Acthar.

The firm remains positive on the stock... More

Mallinckrodt plc (MNK) PT Slashed to $38 at BMO Capital; Keeps 'Outperform'

BMO Capital lowered its price target on Mallinckrodt plc (NYSE: MNK) to $38.00 (from $65.00) while maintaining a Outperform rating following weak Q4 results

Analyst Gary Nachman surprising and disappointing news in 3Q was regarding Acthar, as a sizable shortfall was driven... More